Johan Bratt - Concepedia

Author

Johan Bratt

Karolinska Institutet

Also Known As

J Bratt, J. BRATT, J. Bratt, JOHAN BRATT, Johan Bratt

Publications

1.9K

Citations

H-Index

Concepts

All Affiliations

Karolinska Institutet Karolinska University Hospital Lund University Integrated Cardio Metabolic Centre Helsingborgs lasarett

About

Johan Bratt is an author at Karolinska Institutet specializing in medicine, inflammation, and rheumatology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	717
2	Immunology	4	4	118
3	Health Sciences	2	2	63
4	Allergy	1	1	23
5	Biochemistry	1	1	20

Johan Bratt

Publications

1.8K

Citations

H-Index

Page 1

	Year	Citations
Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial Ronald van Vollenhoven, Sofia Ernestam, P. Geborek, The Lancet InflammationRheumatologyRheumatoid DisorderAnti-inflammatoryAutoimmune Disease	2009	316
Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial Ronald van Vollenhoven, Pierre Geborek, Kristina Forslind, The Lancet Rheumatoid DisorderRheumatologySystemic TreatmentRheumatic DiseasesClinical Trials	2012	223
Predictors of response to methotrexate in early DMARD naïve rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial Saedís Saevarsdóttir, Helena Wallin, Maria Seddighzadeh, Annals of the Rheumatic Diseases	2010	192
Adalimumab (Humira®) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade®) or etanercept (Enbrel®): results from the STURE registry at Karolinska University Hospital Marius C. Wick, Sofia Ernestam, Staffan Lindblad, Scandinavian Journal of Rheumatology	2005	119
In early rheumatoid arthritis, patients with a good initial response to methotrexate have excellent 2-year clinical outcomes, but radiological progression is not fully prevented: data from the methotrexate responders population in the SWEFOT trial Hamed Rezaei, Saedís Saevarsdóttir, Kristina Forslind, Annals of the Rheumatic Diseases	2011	95
Cytokine-induced neutrophil-mediated injury of human endothelial cells Johan Bratt, Jan Palmblad The Journal of Immunology	1997	72
Fcγ receptor type IIIA genotype and response to tumor necrosis factor α–blocking agents in patients with rheumatoid arthritis Alf Kastbom, Johan Bratt, Sofia Ernestam, Arthritis & Rheumatism	2007	64
High-Mobility Group Box-1 Protein (HMGB1) Is Increased in Antineutrophilic Cytoplasmatic Antibody (ANCA)-Associated Vasculitis with Renal Manifestations Annette Bruchfeld, Mårten Wendt, Johan Bratt, Molecular Medicine	2010	62
Anti-apoA-1 IgG and oxidized LDL are raised in rheumatoid arthritis (RA): potential associations with cardiovascular disease and RA disease activity Nicolas Vuilleumier, Johan Bratt, Reyhane Alizadeh, Scandinavian Journal of Rheumatology	2010	55
Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumab Désirée van der Heijde, Maxime Bréban, D Halter, Lara D. Veeken	2014	55

Page 1